New advances in immune mechanism and treatment during ocular toxoplasmosis

Zijian Chen, S. Cheng, Xiaohong Chen, Zuhai Zhang, Yanhua DuFrontiers in Immunology 2024 · DOI

Abstract

Ocular toxoplasmosis (OT) is an intraocular infection caused by the parasite Toxoplasma gondii. OT is manifested as retinal choroiditis and is the most common infectious cause of posterior uveitis. Invasion of the retina by T. gondii leads to disruption of the blood-ocular barrier and promotes the migration of immune cells to the ocular tissues. Cytokines such as IFN-γ and IL-1β are effective for controlling parasite growth, but excessive inflammatory responses can cause damage to the host. In this review, we will discuss in detail the latest advances in the immunopathology and treatment of OT.

Introduction

Toxoplasma gondii is a highly successful obligate intracellular parasite, infecting approximately one-third of the global population. While many infections are asymptomatic, the parasite's migration to the eye can lead to ocular toxoplasmosis (OT), a condition characterized by severe retinal inflammation and potential permanent vision loss. The management of OT presents a significant clinical challenge due to the immune-privileged nature of the eye and the delicate balance required to eliminate the parasite without causing extensive collateral damage to retinal tissues.

Pathophysiology of Dissemination

The dissemination of T. gondii from the gut to distant organs like the eye involves sophisticated manipulation of the host's immune system. The parasite utilizes two primary strategies for movement: direct invasion of the vascular endothelium using its own actin-myosin motor and a "Trojan horse" mechanism where it hitches a ride inside host immune cells, particularly dendritic cells (DCs) and monocytes.

A key breakthrough in understanding this process is the "GABA Hijack." Upon infection, T. gondii stimulates host DCs to produce gamma-aminobutyric acid (GABA). This neurotransmitter acts on GABA-A receptors in an autocrine fashion, inducing a hypermigratory phenotype. This mechanism effectively turns the infected immune cell into a high-speed vehicle, facilitating the parasite's spread across the blood-retina barrier (BRB) and into the central nervous system.

The GABAergic signaling mechanism hijacked by T. gondii to promote dendritic cell migration and systemic dissemination.

The Immunological Tightrope

The host immune response to OT is a "double-edged sword." Pro-inflammatory cytokines such as IFN-γ and IL-1β are critical for controlling tachyzoite replication. However, the resulting inflammatory environment often leads to "bystander damage"—the destruction of non-infected retinal neurons.

Recent research has highlighted the complex roles of other cytokines:

  • IL-17: Traditionally viewed as pro-inflammatory, IL-17 has been found to play a role in maintaining retinal homeostasis and preventing neuronal calcium overload, though its overproduction can still accelerate tissue damage.
  • IL-6: Similar to IL-17, IL-6 exhibits pleiotropic effects, contributing to both the control of the infection and the exacerbation of inflammatory lesions.

Therapeutic Advances

Current "gold standard" treatments, such as the combination of pyrimethamine and sulfadiazine, are limited by significant systemic side effects and an inability to target the latent bradyzoite (cyst) stage. Recent advances are shifting the focus toward more targeted and less toxic interventions.

Localized Delivery and Alternatives

To minimize systemic toxicity, there is a growing trend toward intravitreal injections of clindamycin and dexamethasone. This approach achieves high local drug concentrations directly at the site of infection. Additionally, trimethoprim-sulfamethoxazole is emerging as a safer, more accessible oral alternative with comparable efficacy to traditional regimens.

Novel Biological and Molecular Targets

  • Exosome Therapy: Experimental models using human mesenchymal stem cell (hMSC)-derived exosomes have shown promise in reducing leukocyte infiltration and calming the ocular immune response without the risks associated with whole-cell therapy.
  • TgMyoA Inhibitors: The parasite's unique "gliding motility" depends on a specific motor protein, Myosin A (TgMyoA). Small-molecule inhibitors targeting this protein offer a potential way to halt parasite invasion and dissemination with high specificity.

Conclusion and Future Directions

Despite significant progress in understanding the molecular mechanisms of OT, several hurdles remain. The persistence of latent cysts ensures a lifelong risk of recurrence, and emerging drug-resistant strains necessitate the development of new therapeutic classes and potential vaccines. Future research must focus on translating promising animal model results, such as exosome therapy and TgMyoA inhibition, into human clinical trials to provide more effective and safer options for patients suffering from this sight-threatening disease.

Summary updated

Abstract

Ocular toxoplasmosis (OT) is an intraocular infection caused by the parasite <i>Toxoplasma gondii.</i> OT is manifested as retinal choroiditis and is the most common infectious cause of posterior uveitis. Invasion of the retina by <i>T. gondii</i> leads to disruption of the blood-ocular barrier and promotes the migration of immune cells to the ocular tissues. Cytokines such as IFN-γ and IL-1β are effective for controlling parasite growth, but excessive inflammatory responses can cause damage to the host. In this review, we will discuss in detail the latest advances in the immunopathology and treatment of OT.
BibTeX
@inproceedings{chen2024new,
  author = {Zijian Chen and S. Cheng and Xiaohong Chen and Zuhai Zhang and Yanhua Du},
  title = {{New advances in immune mechanism and treatment during ocular toxoplasmosis}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1403025},
}
Figure